Heron’s mission is to improve patient’s lives by developing best-in-class medicines that address unmet medical needs. By developing novel, patient-focused solutions that apply our innovative science and technologies to proven pharmacological agents.
Our portfolio includes two products approved by the US FDA, SUSTOL® (granisetron) extended release injection and CINVANTITM (aprepitant) injectable emulsion, as well as one product in development, HTX-011, a novel fixed-dose combination of the local anesthetic bupivacaine with the NSAID, meloxicam currently being studied for application into the surgical site to reduce postoperative pain and the need for opioid analgesics for 72 hours